Search results
Showing 3256 to 3270 of 8858 results
More detail about Diagnostics Advisory Committee (DAC) registration, meeting arrangements and types of attendee.
Read the biographies for all members of the NICE antimicrobial evaluation committee.
Highly specialised technologies evaluation committee members
Biographies for each member of the highly specialised technologies evaluation committee.
More detail about Interventional Procedures Advisory Committee (IPAC) registration, meeting arrangements and types of attendee.
Details and meeting dates of the antimicrobials evaluation panel
More detail about Medical Technologies Advisory Committee (MTAC) registration, meeting arrangements and types of attendee.
Home Get involved Our committees NICE committee meetings...
Help make a difference on behalf of the people most affected by our recommendations on our voluntary and community sector forum.
Providing an advisory service for international health organisations, ministries and government agencies whose task is to improve evidence-based decision making in health and social care
Get expert advice and support from NICE International, part of the UK's National Institute for Health and Care Excellence, for a project in your country
This indicator covers the percentage of patients with diabetes, on the register, who have a record of retinal screening in the preceding 12 month. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM98.
This indicator covers the percentage of patients with diabetes, on the register, with a diagnosis of nephropathy (clinical proteinuria) or micro-albuminuria who are currently treated with an ACE-I (or ARBs). It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM95.
This indicator covers the percentage of patients on the CKD register who are treated with an SGLT-2 inhibitor if they have: type 2 diabetes, or no type 2 diabetes and an eGFR 20 ml/min/1.73 m2 to 44 ml/min/1.73 m2 and are currently treated with an ACE inhibitor or angiotensin receptor blocker (ARB) (unless these are contraindicated) or an eGFR 45 ml/min/1.73 m2 to 59 ml/min/1.73 m2, are currently treated with an ACE inhibitor or ARB (unless these are contraindicated) and have a urine albumin-to-creatinine ratio (ACR) of 22.6 mg/mmol or more. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes.
The complete list of all our published indicators, for measuring outcomes that reflect the quality of care or processes, linked by evidence to improved outcomes.
Early value assessment (EVA) guidance on artificial intelligence (AI) technologies for assessing and triaging skin lesions referred to the urgent suspected skin cancer pathway.